Lam Research Corporation $LRCX Holdings Reduced by First American Trust FSB

First American Trust FSB lessened its holdings in shares of Lam Research Corporation (NASDAQ:LRCX) by 30.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,481 shares of the semiconductor company’s stock after selling 13,166 shares during the period. First American Trust FSB’s holdings in Lam Research were worth $2,967,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Lam Research by 6.9% during the 1st quarter. Vanguard Group Inc. now owns 129,152,102 shares of the semiconductor company’s stock worth $9,389,358,000 after acquiring an additional 8,364,375 shares during the period. Nuveen LLC acquired a new stake in Lam Research in the first quarter worth about $604,344,000. Price T Rowe Associates Inc. MD grew its position in Lam Research by 99.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,739,221 shares of the semiconductor company’s stock valued at $417,242,000 after buying an additional 2,864,863 shares in the last quarter. Nordea Investment Management AB increased its stake in Lam Research by 34.1% during the 2nd quarter. Nordea Investment Management AB now owns 10,594,574 shares of the semiconductor company’s stock valued at $1,029,210,000 after buying an additional 2,692,189 shares during the period. Finally, Boston Partners raised its position in shares of Lam Research by 9,978.3% during the 1st quarter. Boston Partners now owns 2,350,362 shares of the semiconductor company’s stock worth $170,787,000 after buying an additional 2,327,041 shares in the last quarter. 84.61% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Bethany Mayer sold 1,298 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $159.99, for a total transaction of $207,667.02. Following the completion of the sale, the director owned 1,652 shares in the company, valued at $264,303.48. This represents a 44.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Douglas R. Bettinger sold 40,080 shares of Lam Research stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $150.60, for a total value of $6,036,048.00. Following the completion of the transaction, the chief financial officer directly owned 987,237 shares in the company, valued at approximately $148,677,892.20. This represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 102,608 shares of company stock worth $14,916,496 in the last 90 days. Insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. BNP Paribas Exane increased their price objective on shares of Lam Research from $80.00 to $140.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $170.00 price objective on shares of Lam Research in a research note on Thursday, October 23rd. Hsbc Global Res raised Lam Research to a “hold” rating in a research note on Tuesday, September 30th. Dbs Bank boosted their price target on shares of Lam Research from $119.40 to $184.20 in a research report on Monday, October 27th. Finally, Mizuho raised their price objective on shares of Lam Research from $162.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-six have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Lam Research presently has an average rating of “Moderate Buy” and a consensus price target of $149.04.

Lam Research Price Performance

Shares of NASDAQ:LRCX opened at $147.46 on Tuesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.21 and a quick ratio of 1.60. The stock has a market capitalization of $185.21 billion, a P/E ratio of 32.48, a P/E/G ratio of 1.68 and a beta of 1.87. The business has a 50-day moving average of $141.60 and a two-hundred day moving average of $110.47. Lam Research Corporation has a fifty-two week low of $56.32 and a fifty-two week high of $167.15.

Lam Research (NASDAQ:LRCX) last issued its quarterly earnings data on Wednesday, October 22nd. The semiconductor company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.04. The business had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.23 billion. Lam Research had a return on equity of 60.60% and a net margin of 29.66%.The firm’s revenue was up 27.7% compared to the same quarter last year. During the same period last year, the business earned $0.86 EPS. Lam Research has set its Q2 2026 guidance at 1.050-1.250 EPS. On average, equities research analysts predict that Lam Research Corporation will post 3.71 EPS for the current fiscal year.

Lam Research Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 7th. Investors of record on Wednesday, December 3rd will be issued a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, December 3rd. Lam Research’s dividend payout ratio (DPR) is 22.91%.

About Lam Research

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.